Characterization of Antiestrogenic Activity of the Chinese Herb, Prunella vulgaris (PV), Using In Vitro and In Vivo (Mouse Xenograft) Models

Source
Collins NH, Lessey EC, DuShell CD, McDonnell DP, et al. Biol Reprod. Feb 2009; 80(2): 375–383. Nov 5, 2008. doi: 10.1095/biolreprod.107.065375

Prunella vulgaris (Xia Ku Cao), a commonly used Chinese herb, has a wide range of reported medicinal activities. By screening multiple herbs using the endometrial cancer cell line, ECC-1, and an alkaline phosphatase detection assay, we found that PV displayed significant antiestrogenic activity. We investigated the possible usefulness of antiestrogenic activity using both in vitro and in vivo models of endometrial function. Using the well-differentiated, hormone-responsive endometrial cell line, ECC-1, PV extract, at concentrations that were not toxic to the cells, significantly reduced alkaline phosphatase activity and cell proliferation in response to estrogen in a dose-dependent manner. The expression of CYR61, an estrogen-induced protein, was blocked in ECC-1 cells by both the antiestrogen ICI 182 780 and PV extract.
Interestingly, PV extract did not appear to directly inhibit estrogen signaling. Rather, we found that its activities were probably related to an ability to function as an aryl hydrocarbon receptor (AHR) agonist in ECC-1 cells. In support of this hypothesis, we noted that PV induced CYP1A1, CYP1B1, and AHR repressor expression in a dose-dependent manner—responses that were blocked by small interfering RNA treatment to reduce AHR and specific AHR antagonists. Ovariectomized immunodeficient RAG-2/gamma(c) knockout mice implanted with human endometrial xenografts developed implants only when treated with estrogen. Mice treated with estrogen and PV tea in their drinking water had fewer and smaller xenograft implants compared with their estrogen-treated counterparts that drank only water (P < 0.05). Analysis of the resulting implants by immunohistochemistry demonstrated persistent estrogen receptor (ER), but reduced proliferation and CYR61 expression. Mouse uterine tissue weight in PV-treated mice was not different from controls, and cycle fecundity of intact C57 female mice was unaffected by PV tea treatment. PV, or Self-heal, exhibits significant antiestrogenic properties, both in vitro and in vivo. This activity is likely due to the ability of PV-activated AHR to interfere with estrogen. This herb may be useful as an adjunct for the treatment of estrogen-dependent processes like endometriosis and breast and uterine cancers. Full characterization of this herb will likely provide new insights into the crosstalk between AHR and ESR1, with potential for therapeutic applications in women. DISCUSSION Herbal medicines are widely used in the United States, with up to one quarter of adults reporting use of such remedies within the past few years [23]. Not surprisingly, the primary physician is often unaware that their patients are using these treatments. The availability and perception that herbal and complementary remedies are safer than prescription medications may have increased the use of these remedies, often leading to self-treatment for a variety of ailments. Failure to recognize side effects of herbal remedies could lead to interactions or unanticipated health consequences. On the other hand, these medicinal agents may have beneficial effects that could be advantageously applied if the mechanisms of action were better understood in the context of Western medicine. There are several conditions affecting women in which herbal therapies have found a niche. These include menopausal symptoms, menstrual disorders, and treatment for benign conditions, such as endometriosis or uterine fibroids [44, 45]. Many traditional US Food and Drug Administration-approved medications for these conditions have significant side effects or expense [45, 46]. Public concerns about hormone replacement using commercially available estrogens or progestins have also increased after the Women's Health Initiative studies were published [47, 48]. Pre- and postmenopausal women are thus actively seeking natural or nontraditional medical approaches for a wide variety of complaints. In the present study, we screened 21 herbs using the alkaline phosphatase assay of Littlefield and coworkers [40] to detect either estrogenic or antiestrogenic characteristics. PV was the only herbal extract that had strong biological activity in this assay. In review of the literature, there is one report that supports this finding. Huang and colleagues [49] studied the Chinese herb Prunella stica based on its use for the treatment of dysmenorrhea. They showed that this herb blocked the proliferation of Ishikawa cells, but did not interfere with prostaglandin production [49]. Similar to that study, we found that PV extract specifically blocked cell proliferation without affecting cell viability in ECC-1 cells. The in vivo studies suggest that PV is effective when taken orally, and functions in vivo to block proliferation of ectopic endometrium in response to estrogen. The apparent reduction in CYR61 and MKI67 expression in the endometriotic implants provides evidence that PV interferes with estrogen receptor (ESR1) actions. The ability of PV to block estrogen action without affecting fecundity in mice suggests that this herb may have advantages for the treatment of women with gynecologic disease. We [12, 13] and others [15, 50–52] have pointed out the relationship between elevated estrogen action and benign endometrial disorders. ESR1 normally declines at the time of implantation, around Cycle Day 19–20 in normal, fertile women [53]. The failure to down-regulate this receptor may be a primary defect leading to altered gene expression patterns seen in endometriosis [1], or the infertility and pregnancy loss in women with polycystic ovary syndrome [12, 14]. Lack of ESR1 down-regulation is a feature of underlying P resistance seen in some women with benign gynecologic disease [1, 2]. Methods to block the inappropriate actions of estrogen during the putative window of implantation could theoretically be helpful and promote improved uterine receptivity toward embryo attachment and implantation. Studies to investigate this possibility are underway. Understanding the mechanism of the antiestrogenic activity of PV would likely be informative for the design of improved therapies for endometriosis. There is increasing interest in the role of the AHR pathways regulated by dioxin (2,3,7,8-tetrachlorodibenzo-p-dioxin [TCDD]) and other environmental toxins in endometriosis. Antagonists of AHR found in food are increasingly being studied [54]. Red clover, thought to have SERM-like activities, is also an AHR ligand [55]. The trihydroxystilbene resveratrol, an active component in red wine, appears to have antagonistic actions via AHR. While many natural flavinoids appear to be AHR antagonists and, therefore, inhibit CYP1A1 expression [56, 57], PV appears to be an AHR agonist with antiestrogenic properties. Like other herbs noted to inhibit estrogen [58, 59], PV uses novel mechanisms to achieve this action. PV appears to activate the AHRE and stimulate AHR target genes in ECC-1 cells. We found little indication that PV had direct effects on ER in endometrial cells. The mechanism of action of PV to inhibit estrogen responses, potentially through regulation of AHR, remains elusive. AHR, besides regulating target genes, also interacts with both the androgen and estrogen receptors [60], and promotes degradation of these receptors through ubiquitin-mediated mechanisms. Direct action of the AHR to compete with ER activity is another possible explanation for the noted effects of PV on estrogen activity in vivo and in vitro. In addition, evidence points to regulatory elements of AHR as targets for estrogen, further complicating this puzzle [61]. Like resveratrol, PV may also act as a competitive antagonist for TCDD, providing yet another beneficial effect of PV on endometriosis in women who consume this herb. Such a mechanism could account for reported improvements in dysmenorrhea seen in women with endometriosis that take PV. There remains much to learn about herbal and complementary treatments, especially given the potential for cross-reactivity and unintended consequences when taken with other pharmaceuticals. Unrecognized properties of nontraditional therapies, including their actions as AHR ligands, could provide new opportunities for safe and effective treatment of disorders that have not been adequately addressed by conventional Western medical treatments. The discovery of the antiestrogenic properties of PV provides such an opportunity. This herbal treatment might now be understood at the molecular level as a treatment that blocks estrogen action in endometriosis, and may protect individuals from environmental factors that favor its development. Unlike resveratrol, found in red wine, which cannot as yet be conveniently consumed by women seeking pregnancy, PV may provide a potent alternative, with potential benefits for both pain and infertility. Further investigation and evaluation of the active component(s) of this herb are currently underway. 1. Burney RO, Talbi S, Hamilton AE, Vo KC, Nyegaard M, Nezhat CR, Lessey BA, Giudice LC. Gene expression analysis of endometrium reveals progesterone resistance and candidate susceptibility genes in women with endometriosis. Endocrinology 2007; 148: 3814 3826 [PubMed] 2. Donaghay M, Lessey BA. Uterine receptivity: alterations associated with benign gynecological disease. Semin Reprod Med 2007; 25: 461 475 [PubMed] 3. MacLaughlin SD, Palomino WA, Mo B, Lewis TD, Lininger RA, Lessey BA. Endometrial expression of Cyr61: a marker of estrogen activity in normal and abnormal endometrium. Obstet Gynecol 2007; 110: 146 154 [PubMed] 4. Hunter DS, Hodges LC, Eagon PK, Vonier PM, Fuchs-Young R, Bergerson JS, Walker CL. Influence of exogenous estrogen receptor ligands on uterine leiomyoma: evidence from an in vitro/in vivo animal model for uterine fibroids. Environ Health Perspect 2000; 108 (suppl 5): 829 834 [PubMed] 5. Bulun SE, Zeitoun KM, Takayama K, Sasano H. Estrogen biosynthesis in endometriosis: molecular basis and clinical relevance. J Mol Endocrinol 2000; 25: 35 42 [PubMed] 6. Ugwumadu AHN, Harding K. Uterine leiomyomata and endometrial proliferation in postmenopausal women treated with the anti-oestrogen tamoxifen. Eur J Obstet Gynecol Reprod Biol 1994; 54: 153 156 [PubMed] 7. Attar E, Bulun SE. Aromatase inhibitors: the next generation of therapeutics for endometriosis? Fertil Steril 2006; 85: 1307 1318 [PubMed] 8. Palomba S, Orio F, Jr, Russo T, Falbo A, Tolino A, Lombardi G, Cimini V, Zullo F. Antiproliferative and proapoptotic effects of raloxifene on uterine leiomyomas in postmenopausal women. Fertil Steril 2005; 84: 154 161 [PubMed] 9. Dawood MY, Ramos J, Khan-Dawood FS. Depot leuprolide acetate versus danazol for treatment of pelvic endometriosis: changes in vertebral bone mass and serum estradiol and calcitonin. Fertil Steril 1995; 63: 1177 1183 [PubMed] 10. Berliäre M, Galant C, Donnez J. The potential oncogenic effect of tamoxifen on the endometrium. Hum Reprod 1999; 14: 1381 1383 [PubMed] 11. Daniel Y, Inbar M, Bar-Am A, Peyser MR, Lessing JB. The effects of tamoxifen treatment on the endometrium. Fertil Steril 1996; 65: 1083 1089 [PubMed] 12. Gregory CW, Wilson EM, Apparao KB, Lininger RA, Meyer WR, Kowalik A, Fritz MA, Lessey BA. Steroid receptor coactivator expression throughout the menstrual cycle in normal and abnormal endometrium. J Clin Endocrinol Metab 2002; 87: 2960 2966 [PubMed] 13. Lessey BA, Palomino WA, Apparao KB, Young SL, Lininger RA. Estrogen receptor-alpha (ER-alpha) and defects in uterine receptivity in women. Reprod Biol Endocrinol 2006; 4 (suppl 1): S9 [PMC free article] [PubMed] 14. Jackson KS, Brudney A, Hastings JM, Mavrogianis PA, Kim JJ, Fazleabas AT. The altered distribution of the steroid hormone receptors and the chaperone immunophilin FKBP52 in a baboon model of endometriosis is associated with progesterone resistance during the window of receptivity. Reprod Sci 2007; 14: 137 150 [PubMed] 15. Bulun SE, Cheng YH, Yin P, Imir G, Utsunomiya H, Attar E, Innes J, Julie Kim J. Progesterone resistance in endometriosis: link to failure to metabolize estradiol. Mol Cell Endocrinol 2006; 248: 94 103 [PubMed] 16. Yildirim Y, Tinar S, Yorgun S, Toz E, Kaya B, Sonmez S, Balsak D. The use of complementary and alternative medicine (CAM) therapies by Turkish women with gynecological cancer. Eur J Gynaecol Oncol 2006; 27: 81 85 [PubMed] 17. Mikail CN, Hearney E, Nemesure B. Increasing physician awareness of the common uses and contraindications of herbal medicines: utility of a case-based tutorial for residents. J Altern Complement Med 2003; 9: 571 576 [PubMed] 18. Nestler G, Dovey M. Traditional Chinese medicine. Clin Obstet Gynecol 2001; 44: 801 813 [PubMed] 19. Pinn G. Herbs used in obstetrics and gynaecology. Aust Fam Physician 2001; 30: 351 354 [PubMed] 20. Shreffler-Grant J, Hill W, Weinert C, Nichols E, Ide B. Complementary therapy and older rural women: who uses it and who does not? Nurs Res 2007; 56: 28 33 [PubMed] 21. Mizrachi N, Shuval JT, Gross S. Boundary at work: alternative medicine in biomedical settings. Sociol Health Illn 2005; 27: 20 43 [PubMed] 22. Cuellar N, Aycock T, Cahill B, Ford J. Complementary and alternative medicine (CAM) use by African American (AA) and Caucasian American (CA) older adults in a rural setting: a descriptive, comparative study. BMC Complement Altern Med 2003; 3: 8 [PMC free article] [PubMed] 23. Gaudet T. Complementary and Alternative Medicine. Clinical Updates in Women's Health Care 2004; III: 1 82 24. Albertazzi P, Pansini F, Bottazzi M, Bonaccorsi G, de Aloysio D, Morton MS. Dietary soy supplementation and phytoestrogen levels. Obstet Gynecol 1999; 94: 229 231 [PubMed] 25. Brzezinski A, Debi A. Phytoestrogens: the “natural” selective estrogen receptor modulators? Eur J Obstet Gynecol Reprod Biol 1999; 85: 47 51 [PubMed] 26. Antoine C, Liebens F, Carly B, Pastijn A, Rozenberg S. Safety of alternative treatments for menopausal symptoms after breast cancer: a qualitative systematic review. Climacteric 2007; 10: 23 26 [PubMed] 27. Geller SE, Studee L. Botanical and dietary supplements for mood and anxiety in menopausal women. Menopause 2007; 14: 541 549 [PubMed] 28. Giannelli M, Cuttini M, Da Fre M, Buiatti E. General practitioners' knowledge and practice of complementary/alternative medicine and its relationship with life-styles: a population-based survey in Italy. BMC Fam Pract 2007; 8: 30 [PMC free article] [PubMed] 29. Taylor M. Alternative medicine and the perimenopause an evidence-based review. Obstet Gynecol Clin North Am 2002; 29: 555 573 [PubMed] 30. Jacobson JS, Workman SB, Kronenberg F. Research on complementary and alternative therapies for cancer: issues and methodological considerations. J Am Med Womens Assoc 1999; 54: 177 180 [PubMed] 31. Chiu LC, Zhu W, Ooi VE. A polysaccharide fraction from medicinal herb Prunella vulgaris downregulates the expression of herpes simplex virus antigen in Vero cells. J Ethnopharmacol 2004; 93: 63 68 [PubMed] 32. Psotova J, Kolar M, Sousek J, Svagera Z, Vicar J, Ulrichova J. Biological activities of Prunella vulgaris extract. Phytother Res 2003; 17: 1082 1087 [PubMed] 33. Psotova J, Svobodova A, Kolarova H, Walterova D. Photoprotective properties of Prunella vulgaris and rosmarinic acid on human keratinocytes. J Photochem Photobiol B 2006; 84: 167 174 [PubMed] 34. Kageyama S, Kurokawa M, Shiraki K. Extract of Prunella vulgaris spikes inhibits HIV replication at reverse transcription in vitro and can be absorbed from intestine in vivo. Antivir Chem Chemother 2000; 11: 157 164 [PubMed] 35. Zheng J, He J, Ji B, Li Y, Zhang X. Antihyperglycemic activity of Prunella vulgaris L. in streptozotocin-induced diabetic mice. Asia Pac J Clin Nutr 2007; 16 (suppl 1): 427 431 [PubMed] 36. Chen ZH, Hurh YJ, Na HK, Kim JH, Chun YJ, Kim DH, Kang KS, Cho MH, Surh YJ. Resveratrol inhibits TCDD-induced expression of CYP1A1 and CYP1B1 and catechol estrogen-mediated oxidative DNA damage in cultured human mammary epithelial cells. Carcinogenesis 2004; 25: 2005 2013 [PubMed] 37. Wormke M, Castro-Rivera E, Chen I, Safe S. Estrogen and aryl hydrocarbon receptor expression and crosstalk in human Ishikawa endometrial cancer cells. J Steroid Biochem Mol Biol 2000; 72: 197 207 [PubMed] 38. Rier S, Foster WG. Environmental dioxins and endometriosis. Toxicol Sci 2002; 70: 161 170 [PubMed] 39. Mo B, Vendrov AE, Palomino WA, DuPont BR, Apparao KB, Lessey BA. ECC-1 cells: a well-differentiated steroid-responsive endometrial cell line with characteristics of luminal epithelium. Biol Reprod 2006; 75: 387 394 [PubMed] 40. Littlefield BA, Gurpide E, Markiewicz L, McKinley B, Hochberg RB. A simple and sensitive microtiter plate estrogen bioassay based on stimulation of alkaline phosphatase in Ishikawa cells: estrogenic action of delta 5 adrenal steroids. Endocrinology 1990; 127: 2757 2762 [PubMed] 41. Budwit-Novotny DA, McCarty KS, Sr, Cox EB, Soper JR, Mutch DG, Creasman WT, Flowers JL, McCarty KS., Jr Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. Cancer Res 1986; 46: 5419 5425 [PubMed] 42. Greenberg LH, Slayden OD. Human endometriotic xenografts in immunodeficient RAG-2/gamma(c)KO mice. Am J Obstet Gynecol 2004; 190: 1788 1795; discussion:1795–1796. [PubMed] 43. Castro-Rivera E, Wormke M, Safe S. Estrogen and aryl hydrocarbon responsiveness of ECC-1 endometrial cancer cells. Mol Cell Endocrinol 1999; 150: 11 21 [PubMed] 44. Davis RN. Alternatives to hormone therapy: a clinical guide to menopausal transition. Adv Nurse Pract 2004; 12: 37 38 [PubMed] 45. Wallach EE, Vlahos NF. Uterine myomas: an overview of development, clinical features, and management. Obstet Gynecol 2004; 104: 393 406 [PubMed] 46. Lessey BA. Medical management of endometriosis and infertility. Fertil Steril 2000; 73: 1089 1096 [PubMed] 47. Majumdar SR, Almasi EA, Stafford RS. Promotion and prescribing of hormone therapy after report of harm by the Women's Health Initiative. JAMA 2004; 292: 1983 1988 [PubMed] 48. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321 333 [PubMed] 49. Huang JC, Ruan CH, Tang K, Ruan KH. Prunella stica inhibits the proliferation but not the prostaglandin production of Ishikawa cells. Life Sci 2006; 79: 436 441 [PubMed] 50. Mishra K, Wadhwa N, Guleria K, Agarwal S. ER, PR and Ki-67 expression status in granulomatous and chronic non-specific endometritis. J Obstet Gynaecol Res 2008; 34: 371 378 [PubMed] 51. Fazleabas AT, Brudney A, Chai D, Langoi D, Bulun SE. Steroid receptor and aromatase expression in baboon endometriotic lesions. Fertil Steril 2003; 80 (suppl 2): 820 827 [PubMed] 52. Bulun SE, Yang S, Fang Z, Gurates B, Tamura M, Sebastian S. Estrogen production and metabolism in endometriosis. Ann N Y Acad Sci 2002; 955: 75 85; discussion:86–88; 396–406. [PubMed] 53. Lessey BA, Killam AP, Metzger DA, Haney AF, Greene GL, McCarty KS., Jr Immunohistochemical analysis of human uterine estrogen and progesterone receptors throughout the menstrual cycle. J Clin Endocrinol Metab 1988; 67: 334 340 [PubMed] 54. Amakura Y, Tsutsumi T, Sasaki K, Nakamura M, Yoshida T, Maitani T. Influence of food polyphenols on aryl hydrocarbon receptor-signaling pathway estimated by in vitro bioassay. Phytochemistry 2008; 69: 3117 3130 [PubMed] 55. Medjakovic S, Jungbauer A. Red clover isoflavones biochanin A and formononetin are potent ligands of the human aryl hydrocarbon receptor. J Steroid Biochem Mol Biol 2008; 108: 171 177 [PubMed] 56. Wilhelmsson A, Whitelaw ML, Gustafsson JA, Poellinger L. Agonistic and antagonistic effects of alpha-naphthoflavone on dioxin receptor function: role of the basic region helix-loop-helix dioxin receptor partner factor Arnt. J Biol Chem 1994; 269: 19028 19033 [PubMed] 57. Gasiewicz TA, Rucci G. Alpha-naphthoflavone acts as an antagonist of 2,3,7, 8-tetrachlorodibenzo-p-dioxin by forming an inactive complex with the Ah receptor. Mol Pharmacol 1991; 40: 607 612 [PubMed] 58. Seidlova-Wuttke D, Hesse O, Jarry H, Christoffel V, Spengler B, Becker T, Wuttke W. Evidence for selective estrogen receptor modulator activity in a black cohosh (Cimicifuga racemosa) extract: comparison with estradiol-17beta. Eur J Endocrinol 2003; 149: 351 362 [PubMed] 59. Viereck V, Emons G, Wuttke W. Black cohosh: just another phytoestrogen? Trends Endocrinol Metab 2005; 16: 214 221 [PubMed] 60. Ohtake F, Baba A, Fujii-Kuriyama Y, Kato S. Intrinsic AhR function underlies cross-talk of dioxins with sex hormone signalings. Biochem Biophys Res Commun 2008; 370: 541 546 [PubMed] 61. Singhal R, Shankar K, Badger TM, Ronis MJ. Estrogenic status modulates aryl hydrocarbon receptor-mediated hepatic gene expression and carcinogenicity. Carcinogenesis 2008; 29: 227 236 [PubMed]

You can leave a response, or trackback from your own site.

Leave a Reply

You must be logged in to post a comment.